MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR): $4.21

0.28 (+7.12%)

POWR Rating

Component Grades














  • Growth is the dimension where MOR ranks best; there it ranks ahead of 86.14% of US stocks.
  • MOR's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • MOR ranks lowest in Quality; there it ranks in the 8th percentile.

MOR Stock Summary

  • With a year-over-year growth in debt of 114.49%, MORPHOSYS AG's debt growth rate surpasses 88.93% of about US stocks.
  • Over the past twelve months, MOR has reported earnings growth of 226.02%, putting it ahead of 92.43% of US stocks in our set.
  • MORPHOSYS AG's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -240.01%, greater than the shareholder yield of merely 2.44% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MORPHOSYS AG are MESO, KGC, RBBN, NGD, and ATNX.
  • MOR's SEC filings can be seen here. And to visit MORPHOSYS AG's official web site, go to

MOR Valuation Summary

  • In comparison to the median Healthcare stock, MOR's price/sales ratio is 250% higher, now standing at 13.3.
  • Over the past 41 months, MOR's price/sales ratio has gone down 32.3.
  • MOR's EV/EBIT ratio has moved up 2.7 over the prior 41 months.

Below are key valuation metrics over time for MOR.

Stock Date P/S P/B P/E EV/EBIT
MOR 2021-08-31 13.3 3.2 -18.6 -41.7
MOR 2021-08-30 12.5 3.0 -17.5 -39.8
MOR 2021-08-27 13.2 3.2 -18.5 -41.5
MOR 2021-08-26 12.9 3.1 -18.0 -40.7
MOR 2021-08-25 13.0 3.1 -18.2 -41.0
MOR 2021-08-24 13.3 3.2 -18.5 -41.6

MOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MOR has a Quality Grade of C, ranking ahead of 47.08% of graded US stocks.
  • MOR's asset turnover comes in at 0.092 -- ranking 273rd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.092 0.803 -0.030
2021-03-31 0.081 0.911 -0.063
2021-03-31 0.081 0.911 -0.063
2020-12-31 0.226 0.972 0.070
2020-09-30 0.261 0.997 0.085
2020-06-30 0.309 1.006 0.117

MOR Stock Price Chart Interactive Chart >

Price chart for MOR

MOR Price/Volume Stats

Current price $4.21 52-week high $10.24
Prev. close $3.93 52-week low $3.70
Day low $4.03 Volume 162,100
Day high $4.21 Avg. volume 68,411
50-day MA $4.77 Dividend yield N/A
200-day MA $5.41 Market Cap 576.47M

MorphoSys AG (MOR) Company Bio

MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Latest News Stream

Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream

Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MORPHOSYS AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

MorphoSys AG: Financial Calendar 2023

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023:

Yahoo | November 28, 2022

Earnings Release: Here's Why Analysts Cut Their MorphoSys AG (ETR:MOR) Price Target To €29.30

Shareholders in MorphoSys AG ( ETR:MOR ) had a terrible week, as shares crashed 26% to €15.50 in the week since its...

Yahoo | November 19, 2022

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

PLANEGG, Germany, November 16, 2022--Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

Yahoo | November 16, 2022

MorphoSys Nosedives after Alzheimer’s Drug Fails Trial

Shares of commercial-stage biopharmaceutical company MorphoSys (NASDAQ:MOR) are tanking in the pre-market session today after partner Roche (RHHBY) reported that its drug gantenerumab failed to meet the primary endpoint in the GRADUATE studies for the treatment of Alzheimer’s disease. The drug was not able to demonstrate a slowing clinical decline and the level of beta-amyloid removal came in lower than anticipation. Topline findings from the studies are expected to be presented on November 30 at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Shares of the company are down ~44% year-to-date.

Kailas Salunkhe on TipRanks | November 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning!

William White on InvestorPlace | November 14, 2022

Read More 'MOR' Stories Here

MOR Price Returns

1-mo -14.08%
3-mo N/A
6-mo -22.47%
1-year -55.45%
3-year -87.01%
5-year N/A
YTD -55.31%
2021 -66.76%
2020 -20.55%
2019 40.99%
2018 N/A
2017 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6448 seconds.